Recruiting
Phase 1

FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies

Sponsor:

Foghorn Therapeutics Inc.

Code:

NCT04891757

Conditions

Advanced Hematologic Malignancy

Relapsed Acute Myeloid Leukemia

Refractory Acute Myeloid Leukemia

Relapsed Myelodysplastic Syndromes

Refractory Myelodysplastic Syndromes

Eligibility Criteria

Sex: All

Age: 16+

Healthy Volunteers: Not accepted

Interventions

FHD-286

Low Dose Cytarabine

Decitabine

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information